ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Xinmiao Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzh…. Hauptthemen laut MEDLINE: Activating Transcription Factor 3, Hepatic Stellate Cells, Liver Cirrhosis, Chemokines, CXC. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Wenzhou Municipal Science and Technology Bureau.
Abstract (Originalsprache)
Background and aims Myofibroblasts, the primary producers of extracellular matrix, primarily originate from hepatic stellate cells (HSCs), and their activation plays a pivotal role in liver fibrosis. This study aimed to investigate the function of CXC motif ligand 14 (CXCL14) in the progression of liver fibrosis. Approach and results CXCL14 knockdown significantly reduced the extent of liver fibrosis. Using Ingenuity pathway analysis and qRT‐PCR, activating transcription factor 3 (ATF3) was identified as a key upstream regulator of CXCL14 expression. Mechanistically, ATF3 was shown to bind to the CXCL14 promoter, promoting its transactivation by TGF‐β in HSCs. Notably, both global CXCL14 deletion ( CXCL14 −/− ) and HSC/myofibroblast‐specific CXCL14 knockdown significantly attenuated liver fibrosis in mice. RNA‐seq comparisons between CXCL14 −/− and WT mice highlighted Jak2 as the most significantly downregulated gene, implicating its role in the antifibrotic effects of CXCL14 suppression on HSC inactivation. Moreover, Jak2 overexpression reversed the inhibition of liver fibrosis caused by CXCL14 knockdown in vivo. Conclusions These findings unveil a novel ATF3/CXCL14/Jak2 signalling axis in liver fibrosis, presenting potential therapeutic targets for the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Jianjian Zheng
Förderung
- National Natural Science Foundation of China
- Wenzhou Municipal Science and Technology Bureau
Zitieren
APA
Li, X., Lin, L., Li, Y., Zhang, W., Lang, Z., & Zheng, J. (2024). ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70040
Vancouver
Li X, Lin L, Li Y, Zhang W, Lang Z, Zheng J. ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.70040
BibTeX
@article{Li2024,
author = {Li, Xinmiao and Lin, Lifan and Li, Yifei and Zhang, Weizhi and Lang, Zhichao and Zheng, Jianjian},
title = {ATF3‐mediated transactivation of CXCL14 in HSCs during liver fibrosis},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.70040}
}
EUVIMED